TC Biopharm receives non-compliance notice from Nasdaq

TC Biopharm has received written notification from the listing qualifications staff of Nasdaq indicating that the company has not regained compliance with the minimum Market Value of Listed Securities of $35M required for continued listing on Nasdaq. The company intends to request a hearing which will stay the suspension or delisting action pending the hearing and the expiration of any extension period granted by the Panel following the hearing. TC Biopharm intends to present the Nasdaq panel with a comprehensive plan to address the current deficiency in relation to the market value of the Company’s listed securities to maintain the Nasdaq listing. Consequently, the company’s ADSs and Warrants will remain listed on The Nasdaq Capital Market at least until the Panel renders a decision following the hearing management is confident in its plan of compliance and the business model. The notification has no immediate effect on the listing of the shares, and the stock will continue to trade on Nasdaq under the symbol "TCBP".